Floatz logo

e7386

Liver Neoplasms

Eisai Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Liver Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Tehran University of Medical Sciences
Phase 4BBB
Eloxatin
Shanghai Zhongshan Hospital
Phase 4BB
ALBUMIN AGGREGATED
Sirtex Medical
Phase 4BB
CHLORHEXIDINE
Changhua Christian Hospital
Phase 4BB
Talaporfin
Light Sciences Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

e7386 is also rated in:

colorectal neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
endometrial cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →